voxelotor
Code | Size | Price |
---|
TAR-T7581-5mg | 5mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7581-10mg | 10mg | £130.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7581-25mg | 25mg | £168.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7581-50mg | 50mg | £230.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7581-100mg | 100mg | £367.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7581-200mg | 200mg | £511.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
voxelotor is an inhibitor of sickle hemoglobin (HbS)
CAS:
1446321-46-5
Formula:
C19H19N3O3
Molecular Weight:
337.379
Purity:
0.9994
SMILES:
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O
References
Shu P, You G, Li W, et al.Cefmetazole sodium as an allosteric effector that regulates the oxygen supply efficiency of adult hemoglobin.Journal of Biomolecular Structure and Dynamics.2023: 1-15.
Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease[J]. Hematology Reports, 2018, 10(2).
Hutchaleelaha A , Patel M , Washington C , et al. Pharmacokinetics and Pharmacodynamics of Voxelotor (GBT440) in Healthy Adults and Patients With Sickle Cell Disease[J]. British Journal of Clinical Pharmacology, 2019.